Dr. Peter L. Anderson's lab focuses on improving HIV treatment methods through the development of personalized medication dosing strategies. The research aims to validate a system that allows patients to collect their own samples and test drug levels easily at home. This work is critical for optimizing long-acting antiretroviral therapies, ensuring that each patient's treatment is tailored to their unique needs, ultimately enhancing health outcomes for individuals living with HIV.

Dr. James Christopher Costello's lab at the University of Colorado Denver focuses on understanding Down syndrome by examining how the genes on chromosome 21 influence various co-occurring health conditions. The lab uses innovative computational techniques, particularly in 'omics' data analysis, to find specific signals related to these diseases. Their work aims to improve care not only for individuals with Down syndrome but also for the broader community.

Dr. Jared Brown's lab at the University of Colorado Denver focuses on understanding how certain environmental exposures, particularly silica from burning agricultural crops, contribute to chronic kidney disease. His research also explores the role of mast cells in lung injury caused by chemical pollutants. By investigating these critical health issues, the lab aims to develop predictive models and potential treatments for diseases related to environmental toxins.

Dr. Tatiana G Kutateladze's lab studies how certain chemical changes in the molecular structure of DNA and proteins, known as epigenetic modifications, influence aging and diseases like Alzheimer's. Their research focuses on a specific modification on histones, the proteins that package DNA, and how this impacts gene expression and cellular function. By understanding these processes, the lab aims to find new ways to prevent or treat age-related disorders.

Dr. Christopher Peter Ford's lab focuses on understanding how dopamine signals contribute to movement and learning processes in the brain. By studying the mechanisms of dopamine transmission, the research aims to determine how these signals impact motor activities and their dysfunction in conditions like Parkinson's disease. The lab employs innovative methods to explore different dopamine release patterns and their effects on behavior, striving for insights that could lead to improved treatments for motor disorders.

Dr. Heide L. Ford's lab focuses on understanding the mechanisms behind aggressive pediatric cancers like Rhabdomyosarcoma (RMS) and Triple Negative Breast Cancer (TNBC). Their research aims to uncover how specific transcription factors influence tumor growth and differentiation, potentially leading to targeted therapies that minimize toxicity. By combining advanced genetic tools and animal models, the team seeks to develop better treatments for these challenging cancers.

Jed Noah Lampe's lab focuses on understanding the interactions between drugs and hormones, particularly in vulnerable populations like pregnant individuals. The lab conducts research to improve the safety of antiviral medications and to explore how pathogens, specifically the bacterium Pseudomonas aeruginosa, affect drug metabolism in patients with cystic fibrosis. By studying these interactions, the lab aims to prevent harmful side effects and develop better treatment strategies for infections and drug therapies.

Dr. Melanie S. Joy's lab at the University of Colorado Denver focuses on understanding how cancer immunotherapy, specifically immune checkpoint inhibitors (ICIs), can cause kidney damage. The research aims to develop preclinical models that simulate human conditions to study these kidney toxicities and identify ways to predict and detect these side effects early in cancer patients. The lab combines innovative animal models with clinical evaluations to bridge laboratory findings and patient care.

Dr. Dmitri Simberg's lab focuses on developing innovative drug delivery systems using lipid nanoparticles for treating invasive glioblastoma, a highly aggressive brain tumor. The research aims to enhance the effectiveness of drug therapies by overcoming barriers in the brain and targeting tumor cells directly. By understanding the trafficking and formulation of lipid-based nanoparticles, the lab seeks to improve treatment outcomes for patients with this challenging disease.

Dr. Manisha N Patel's lab at the University Of Colorado Denver focuses on understanding how mitochondria, the energy powerhouses of cells, contribute to neuroinflammation and astrogliosis in epilepsy. By investigating the role of mitochondrial reactive oxygen species (mtROS) in neuronal-glial communication, the lab aims to identify potential new therapies for treating epilepsy. The research combines various techniques to explore how oxidative stress impacts brain function and inflammation in seizure models.

Dr. Thomas Anchordoquy's research lab at the University of Colorado Denver focuses on improving cancer chemotherapy by developing strategies to minimize the off-target accumulation of drug-containing nanoparticles in healthy tissues. This innovative approach leverages the immune response to enhance drug delivery specifically to tumors while reducing adverse effects. The lab's work is essential in finding ways to make cancer treatments more effective and less toxic for patients.

Dr. James Roede's lab at the University of Colorado Denver focuses on understanding how environmental chemicals affect neurodevelopment, particularly in individuals with Down syndrome. They study specific cellular mechanisms that may lead to cognitive challenges in this population, exploring the role of toxic compounds and how they interact with genetic factors. The lab employs advanced techniques to investigate changes at the cellular and molecular levels that contribute to cognitive variability in Down syndrome.

Dr. Matthew J. Kennedy's lab at the University of Colorado Denver focuses on understanding how the tiny structures within synapses, which are connections between neurons, influence brain function. They are developing innovative tools to manipulate these structures in real time, which will help reveal their role in important cognitive processes, such as learning and memory. This research aims to bridge the gap between the molecular dynamics of synapses and their impact on cognitive functions, potentially shedding light on brain disorders linked to synaptic dysfunction.

Dr. Mark L Dell'Acqua's lab at the University of Colorado Denver focuses on understanding how amyloid beta, a protein involved in Alzheimer's disease, disrupts synaptic function in the brain. The lab investigates the molecular signaling pathways that control synaptic plasticity—the brain's ability to adapt and change. By studying these pathways, the research aims to identify potential therapeutic targets that could help preserve cognitive function in individuals affected by Alzheimer's disease.